BRPI0718679A2 - Composto, molécula de dna, e, métodos para tratar um paciente com tecido cardíaco danificado, para tratar um paciente para reparar cartilagem danificada e para tratar um paciente para reparar tecido do nervo danificado - Google Patents

Composto, molécula de dna, e, métodos para tratar um paciente com tecido cardíaco danificado, para tratar um paciente para reparar cartilagem danificada e para tratar um paciente para reparar tecido do nervo danificado Download PDF

Info

Publication number
BRPI0718679A2
BRPI0718679A2 BRPI0718679-7A2A BRPI0718679A BRPI0718679A2 BR PI0718679 A2 BRPI0718679 A2 BR PI0718679A2 BR PI0718679 A BRPI0718679 A BR PI0718679A BR PI0718679 A2 BRPI0718679 A2 BR PI0718679A2
Authority
BR
Brazil
Prior art keywords
seq
igf
compound
fusion protein
patient
Prior art date
Application number
BRPI0718679-7A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Richard Lee
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of BRPI0718679A2 publication Critical patent/BRPI0718679A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
BRPI0718679-7A2A 2006-11-13 2007-11-08 Composto, molécula de dna, e, métodos para tratar um paciente com tecido cardíaco danificado, para tratar um paciente para reparar cartilagem danificada e para tratar um paciente para reparar tecido do nervo danificado BRPI0718679A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85840606P 2006-11-13 2006-11-13
US60/858406 2006-11-13
US11/979708 2007-11-07
US11/979,708 US9187517B2 (en) 2006-11-13 2007-11-07 Methods of promoting cardiac repair using growth factors fused to heparin binding sequences
PCT/US2007/023527 WO2008063424A2 (en) 2006-11-13 2007-11-08 Methods of promoting cardiac repair using growth factors fused to heparin binding sequences

Publications (1)

Publication Number Publication Date
BRPI0718679A2 true BRPI0718679A2 (pt) 2014-02-04

Family

ID=39430287

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0718679-7A2A BRPI0718679A2 (pt) 2006-11-13 2007-11-08 Composto, molécula de dna, e, métodos para tratar um paciente com tecido cardíaco danificado, para tratar um paciente para reparar cartilagem danificada e para tratar um paciente para reparar tecido do nervo danificado

Country Status (13)

Country Link
US (2) US9187517B2 (enExample)
EP (1) EP2091550B1 (enExample)
JP (1) JP2010508845A (enExample)
KR (1) KR20090087061A (enExample)
AU (1) AU2007322217A1 (enExample)
BR (1) BRPI0718679A2 (enExample)
CA (1) CA2670830A1 (enExample)
IL (1) IL198708A0 (enExample)
MX (1) MX2009005090A (enExample)
NO (1) NO20092261L (enExample)
NZ (1) NZ577235A (enExample)
RU (1) RU2009122456A (enExample)
WO (1) WO2008063424A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187517B2 (en) * 2006-11-13 2015-11-17 The Brigham And Women's Hospital, Inc. Methods of promoting cardiac repair using growth factors fused to heparin binding sequences
US8691771B2 (en) * 2010-05-21 2014-04-08 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins for tissue repair
JP2012093290A (ja) * 2010-10-28 2012-05-17 Sumitomo Bakelite Co Ltd 医療用粒子および生理活性物質の捕捉方法
US9421245B2 (en) * 2012-06-25 2016-08-23 The Brigham And Women's Hospital, Inc. Targeted therapeutics
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
WO2014004467A1 (en) * 2012-06-25 2014-01-03 The Brigham And Women's Hospital, Inc. Selective cartilage therapy
CA3000742A1 (en) 2015-10-02 2017-04-06 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair
EA037848B1 (ru) * 2016-07-14 2021-05-27 Общество С Ограниченной Ответственностью "Биохимический Агент" Гибридный белок, полинуклеотид, генетическая конструкция, продуцент, препарат для регенерации хряща (варианты)
JP2021516966A (ja) 2018-03-09 2021-07-15 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 組織への生物学的薬物の送達

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670483A (en) * 1992-12-28 1997-09-23 Massachusetts Insititute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
US5723331A (en) * 1994-05-05 1998-03-03 Genzyme Corporation Methods and compositions for the repair of articular cartilage defects in mammals
EP0920490A2 (en) * 1996-07-25 1999-06-09 Genzyme Corporation Chondrocyte media formulations and culture procedures
AUPP298498A0 (en) * 1998-04-17 1998-05-07 Gropep Pty Ltd Matrix binding factor
AU2001288392A1 (en) * 2000-08-30 2002-03-13 University Of Delaware Delivery system for heparin-binding growth factors
CA2496732A1 (en) 2002-08-20 2004-03-04 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US7166574B2 (en) * 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US7598224B2 (en) * 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
WO2005014619A2 (en) * 2003-03-28 2005-02-17 Thomas Jefferson University Heparin-binding peptides and uses thereof
US20080227696A1 (en) * 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
US7399831B2 (en) * 2004-10-25 2008-07-15 The Brigham And Women's Hospital, Inc. Targeted delivery of biological factors using self-assembling peptide nanofibers
AU2005323062A1 (en) * 2005-01-04 2006-07-13 The Brigham And Women's Hospital, Inc. Sustained delivery of PDGF using self-assembling peptide nanofibers
US9187517B2 (en) * 2006-11-13 2015-11-17 The Brigham And Women's Hospital, Inc. Methods of promoting cardiac repair using growth factors fused to heparin binding sequences

Also Published As

Publication number Publication date
US20080138323A1 (en) 2008-06-12
IL198708A0 (en) 2011-08-01
US20160024170A1 (en) 2016-01-28
JP2010508845A (ja) 2010-03-25
MX2009005090A (es) 2009-07-24
KR20090087061A (ko) 2009-08-14
NO20092261L (no) 2009-08-06
EP2091550A4 (en) 2009-12-09
WO2008063424A3 (en) 2008-09-12
US9187517B2 (en) 2015-11-17
EP2091550B1 (en) 2013-01-02
RU2009122456A (ru) 2010-12-20
EP2091550A2 (en) 2009-08-26
WO2008063424A2 (en) 2008-05-29
US9969788B2 (en) 2018-05-15
AU2007322217A1 (en) 2008-05-29
NZ577235A (en) 2011-12-22
CA2670830A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
US9969788B2 (en) Methods of treating damaged cartilage tissue using growth factors fused to heparin binding sequences
Duffy et al. Human blood-brain barrier insulin-like growth factor receptor
King et al. Direct demonstration of separate receptors for growth and metabolic activities of insulin and multiplication-stimulating activity (an insulinlike growth factor) using antibodies to the insulin receptor
Zachary et al. Early events elicited by bombesin and structurally related peptides in quiescent Swiss 3T3 cells. I. Activation of protein kinase C and inhibition of epidermal growth factor binding.
De Vroede et al. Modulation of insulinlike growth factor I binding to human fibroblast monolayer cultures by insulinlike growth factor carrier proteins released to the incubation media.
US5434133A (en) CNP analog peptides and their use
JP5993827B2 (ja) ミオスタチンアンタゴニスト
JP2010508845A5 (enExample)
CN1774448B (zh) 生长因子复合物及细胞迁移和生长的调节
Lamphere et al. Components of signaling pathways for insulin and insulin-like growth factor-I in muscle myoblasts and myotubes
US4980279A (en) Cellular fibronectin: polypeptides, anti-polypeptide antibodies and assay methods
US20080125373A1 (en) MNTF peptides and compositions and methods of use
WO2020246900A1 (en) Bioactive agents and methods related thereto
Kitajima et al. A chimeric epidermal growth factor with fibrin affinity promotes repair of injured keratinocyte sheets
EP2056868B1 (en) Inhibition of angiogenesis, tumorigenesis and cathepsin activity using insulin-like growth factor binding protein
EP1071718A1 (en) Matrix binding factor
Upton et al. Production and characterization of recombinant chicken insulin-like growth factor-II from Escherichia coli
HUT70297A (en) Human bone derived insulin like growth factor binding protein
Cai et al. Purification and characterization of an endothelial cell-viability maintaining factor from fetal bovine serum
US5622935A (en) Medicine for preventing and curing bone fracture
AU2003287289B2 (en) Promotion of peroxisomal catalase function in cells
CN101547704A (zh) 使用融合至肝素结合序列的生长因子促进心脏修复的方法
SHIU et al. Characterization of insulin-like growth factor II peptides secreted by explants of neonatal brain and of adult pituitary from rats
CA2853204A1 (en) Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases
KR20170143216A (ko) Fndc5를 포함하는 융합 단백질 및 이의 용도

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2277 DE 26/08/2014.